Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US House Committee Requests Proof Of FDA Progress Seizing Opioids In International Mail

Executive Summary

Energy & Commerce's Republican and Democrat leadership ask FDA Commissioner Scott Gottlieb about work by the agency's Office of Criminal Investigations focused on opioid drugs, the office's staffing and its priorities. They note FDA's FY2018 appropriation included $94m for its work in international mail facilities.

You may also be interested in...



Over-Legislating On Opioids? US FDA May Get New Authorities And Unwanted Tasks

In the face of the overwhelming opioid abuse epidemic, it is hard to argue against doing more. But, at least when it comes to some of the FDA-related bills pending, there is a good argument that Congress is in danger of over-legislating.

Opioid Drug Sales Online Draw US FDA Warnings, Prompt Summit Meeting

At June 27 "Online Opioid Summit," FDA officials, pharma sales researchers, and industry stakeholders will discuss collaborating for stronger impact against the opioid crisis by reducing the availability of illicit products online."The internet is virtually awash in illegal narcotics and we’re going to be taking new steps to work with legitimate internet firms to voluntarily crack down on these sales," says Commissioner Scott Gottlieb.

Opioid Withdrawal Treatment Claims Spur FDA's Latest Kratom Warnings

Related Content

Topics

UsernamePublicRestriction

Register

ID020288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel